FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance - Wikidata - awgldk - TriplyDB

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

http://www.wikidata.org/entity/Q33607015

about

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

http://www.wikidata.org/entity/Q33607015

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@ast

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@en

type

label

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@ast

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@en

prefLabel

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@ast

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@en

P1433

Q33607015-29376748-AD54-4C1E-A97C-D56D03D23B35

P1476

Q33607015-4627663C-24B0-43EB-8CB8-C19A538D8261

P2093

Q33607015-2621D8A2-5E33-4DA8-A979-52497ADAEC8E

Q33607015-2A70873A-8FF3-4F54-81DF-282D0C6F5FAC

Q33607015-2B8C0C99-804D-4604-A877-3A87CEC4B1B5

Q33607015-34A2B59B-BD23-4144-A26A-378F554322AA

Q33607015-3E381B40-EEED-4D81-B97A-C2D9BA09AD83

Q33607015-6BF6D407-3CC9-4BEE-948B-2FA6E3A6379D

Q33607015-92B3FCCB-D296-4D10-8B6F-73EAF26ED73E

Q33607015-BA52245B-986B-4C0D-820E-A17A03808FF3

Q33607015-CA4FCA21-03F3-4909-A540-29642B1EEC28

P2860

Q33607015-0404A5A6-6243-49C8-AC21-9CB31DA75A70

Q33607015-067C505B-63FC-46FC-8356-36D77DEE8C9B

Q33607015-19BD4594-5B98-4601-A8F3-4DD06B6E2B75

Q33607015-24277445-9FFB-45A0-A7B1-E6EB623B0C9A

Q33607015-33EC17C2-F5DE-4ECA-AE67-C93A718EFDD0

Q33607015-36A572B1-8AD1-4D2A-B188-6ACC8C78B592

Q33607015-39332BF8-B076-488F-9BBA-BEBDE53DE159

Q33607015-3983B517-8A96-40CE-B2AB-6013C820C7F3

Q33607015-3F9C3971-7C1B-4CC2-8C3F-F9C900655866

Q33607015-44F44985-562E-48D3-B68B-DFA8A582E45E

P304

Q33607015-45C3FB09-1F76-4E51-90D6-D3B04D4D04B7

P31

Q33607015-99C06FB0-B956-439B-8B38-9EB0FE614F05

P356

Q33607015-AC07A02C-106D-4D0F-8091-C5AA01FA8D6D

P478

Q33607015-00F50539-221C-4F56-A275-3E98BD709E96

P50

Q33607015-1BB8144E-9323-4136-B6BE-83E25AC39C9D

Q33607015-7003EDEB-8D39-4964-B7EA-943DDAD91E8A

Q33607015-E2C50754-09BF-4937-932B-814A105235AD

P577

Q33607015-91A0CB03-302C-4B71-A801-1F31FE323C03

P698

Q33607015-E76FEA33-0F16-459F-B310-A58BCF3A80CE

P932

Q33607015-520D48E4-B1BE-4ECE-A0E9-A3248610197B

P356

FIMMU.2017.00457

P1433

Frontiers in Immunology

P1476

FCγ Chimeric Receptor-Engineer ...... ations, and Clinical Relevance

@en

P2093

Andrea Coppola

http://www.w3.org/2001/XMLSchema#string

Davide Lauro

http://www.w3.org/2001/XMLSchema#string

Giulia Lanzilli

http://www.w3.org/2001/XMLSchema#string

Giuseppe Sconocchia

http://www.w3.org/2001/XMLSchema#string

Luca Maurillo

http://www.w3.org/2001/XMLSchema#string

Maria Ilaria Del Principe

http://www.w3.org/2001/XMLSchema#string

Roberto Arriga

http://www.w3.org/2001/XMLSchema#string

Soldano Ferrone

http://www.w3.org/2001/XMLSchema#string

Tommaso Sconocchia

http://www.w3.org/2001/XMLSchema#string

P2860

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

Effector memory T cells, early metastasis, and survival in colorectal cancer.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

P304

457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2017.00457

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Buccisano

Adriano Venditti

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28496440

http://www.w3.org/2001/XMLSchema#string

P932

5406408

http://www.w3.org/2001/XMLSchema#string